H.C. Wainwright raised the firm’s price target on Nuvalent (NUVL) to $155 from $130 and keeps a Buy rating on the shares. The firm cites the positive ALKOVE-1 data for the increase. Nuvalent is well positioned to become a commercial entity by the end of 2026, says the analyst, who expects zildesamtinib to receive accelerated approval as a therapy for ROS1-positive lung cancer from the FDA during Q3 of 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL: